Filter by: patients
Home > Community Treatment Reports and Side Effects > Depas Treatment Report
What is Depas?

Etizolam (marketed under the brand name Sedekopan or Depas) is a drug which is a benzodiazepine derivative. It possesses anxiolytic, anticonvulsant, sedative and skeletal muscle relaxant properties. Etizolam is not approved for sale in the United States or Canada.

Reported Purpose & Efficacy

Reasons and Efficacy
Purpose # of patients
# of patients with evaluations Efficacy
Major
Moderate
Slight
None
Can’t tell
Treat my mood condition(s) 2 1 Efficacy_moderate

See all 2 patients currently taking Depas

Mouse over the table for more information

Reported Side Effects

Side effects as an overall problem

Severe
 0
Moderate
 1
Mild
 0
None
 0

Commonly reported side effects, conditions, and hospitalizations associated with Depas

Memory problems 1

Reported Dosages

  2 mg daily 3 mg daily
  1 Number of Patients: 1 1 Number of Patients: 1  

Reported Adherence, Burden & Cost See details from patient evaluations ▼

Adherence

Taking treatment as prescribed

Adherence of Depas

Always
 0 0%
Usually
 0 0%
Sometimes
 1 100%
Never
 0 0%

Burden

Difficulty being on treatment

Burden of Depas

Very
 0 0%
Somewhat
 0 0%
A little
 0 0%
Not at all
 1 100%

Cost

Paid out of pocket

Cost of Depas

$200+
 0 0%
$100-199
 0 0%
$50-99
 0 0%
$25-49
 0 0%
< $25
 1 100%

Report created on May 28, 2012.